CytomX Therapeutics (6C1) Stock Statistics & Valuation Metrics

CytomX Therapeutics has a market cap or net worth of CHF591.31M. The enterprise value is CHF495.53.

CytomX Therapeutics has 217,899,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

CytomX Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -20.48%.

The current PE Ratio of CytomX Therapeutics is ―. CytomX Therapeutics’s PEG ratio is 0.20.

In the last 12 months, CytomX Therapeutics had revenue of 76.20M and earned -17.37M in profits. Earnings per share was -0.15.

In the last 12 months, operating cash flow was -82.41M and capital expenditures -74.00K, giving a free cash flow of -82.48M billion.

CytomX Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

CytomX Therapeutics upcoming earnings date is Nov 10, 2026, After Close (Confirmed).

CytomX Therapeutics as a current ratio of 3.09, with Debt / Equity ratio of 1.89%

In the past 12 months, CytomX Therapeutics has paid 238.00K in taxes.

CytomX Therapeutics EV to EBITDA ratio is -36.76, with an EV/FCF ratio of -7.64.

CytomX Therapeutics has CHF330.28M in cash and marketable securities with CHF5.70M in debt, giving a net cash position of CHF324.58M billion.

Gross margin is 98.63%, with operating margin of -29.35%, and net profit margin of -22.79%.

The average price target for CytomX Therapeutics is CHF10.24, which is 11.43% higher than the current price. The consensus rating is Strong Buy